Comparing Two Chemotherapy Regimens for Testicular Cancer
Author Information
Author(s): R de Wit, G Stoter, DTh Sleijfer, JP Neijt, WW ten Bokkel Huinink, L de Prijck, L Collette, R Sylvester
Primary Institution: Rotterdam Cancer Institute and University Hospital
Hypothesis
Is ifosfamide superior to bleomycin in combination with cisplatin and etoposide for treating intermediate-prognosis metastatic testicular non-seminoma?
Conclusion
The study found no significant difference in efficacy between the two chemotherapy regimens, but VIP was more toxic.
Supporting Evidence
- Complete response rates were similar for both treatments, with 79% for BEP and 74% for VIP.
- After surgery, 82% of patients on BEP and 80% on VIP were rendered disease-free.
- VIP showed significantly higher toxicity, with 89% experiencing severe leucocytopenia compared to 37% on BEP.
Takeaway
Doctors wanted to see if a new medicine was better than an old one for treating a type of cancer, but they found out they worked about the same.
Methodology
Patients were randomized to receive either BEP or VIP chemotherapy and were monitored for response and toxicity.
Limitations
The study was prematurely discontinued due to data from a competing study showing no improved effectiveness of VIP compared to BEP.
Participant Demographics
Patients had intermediate-prognosis metastatic testicular non-seminoma.
Statistical Information
P-Value
0.62
Confidence Interval
95% CI 74-96%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website